Akebia Ther

Yahoo Finance • 8 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees op... Full story

Yahoo Finance • 16 days ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present d... Full story

Yahoo Finance • 20 days ago

Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday?

We recently published a list of Thursday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday’s worst-performing stocks. Wall Street’s mai... Full story

Yahoo Finance • 21 days ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing... Full story

Yahoo Finance • 22 days ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has... Full story

Yahoo Finance • last month

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 20... Full story

Yahoo Finance • 2 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees opt... Full story

Yahoo Finance • last year

Akebia Therapeutics to Present at Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Execut... Full story

Yahoo Finance • last year

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript November 8, 2023 Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.09. Operator: Good day and thank you for stand... Full story

Yahoo Finance • 2 years ago

Akebia Announces Swissmedic Approval of Vafseo® (vadadustat)

CAMBRIDGE, Mass., June 20, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization for Vafseo® (vadadustat), an oral hyp... Full story

Yahoo Finance • 3 years ago

Akebia Therapeutics to Report Second Quarter Financial Results

Akebia to Host Conference Call to Provide Business Update CAMBRIDGE, Mass., July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kid... Full story

Yahoo Finance • 3 years ago

AKBA FINAL DEADLINE FRIDAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important May 13 Deadline in Securities Class Action – AKBA

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (... Full story

Yahoo Finance • 3 years ago

AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Akebia Therapeutics, Inc. (NASDAQ: AKBA)

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been file... Full story

Yahoo Finance • 3 years ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm

NEW YORK, May 08, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Akebia Therapeutics, Inc.... Full story

Yahoo Finance • 3 years ago

ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important May 13 Deadline in Securities Class Action – AKBA

NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (t... Full story

Yahoo Finance • 3 years ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Rivian, Akebia, Grab, and Celsius and Encourages Investors to Contact the Firm

NEW YORK, May 02, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Rivian Automotive, Inc. (N... Full story

Yahoo Finance • 3 years ago

RIVN, AKBA & SFM Upcoming Class Action Deadlines: Bronstein, Gewirtz & Grossman, LLC, A Recognized Class Action Firm, Reminds Investors to Contact the Firm

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy o... Full story

Yahoo Finance • 3 years ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ericsson, C3.ai, Rivian, and Akebia and Encourages Investors to Contact the Firm

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Telefonaktiebolaget LM E... Full story

Yahoo Finance • 3 years ago

ROSEN, A TOP RANKED FIRM, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important May 13 Deadline in Securities Class Action – AKBA

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive... Full story

Yahoo Finance • 3 years ago

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA

NEW YORK, April 22, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive... Full story